<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="case-report" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MCO</journal-id>
<journal-title-group>
<journal-title>Molecular and Clinical Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2049-9450</issn>
<issn pub-type="epub">2049-9469</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">MCO-16-4-02510</article-id>
<article-id pub-id-type="doi">10.3892/mco.2022.2510</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>BCOR-CCNB3</italic> sarcoma arising in the proximal tibia: A case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Suzuki</surname><given-names>Kayo</given-names></name>
<xref rid="af1-MCO-16-4-02510" ref-type="aff">1</xref>
<xref rid="c1-MCO-16-4-02510" ref-type="corresp"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yasuda</surname><given-names>Taketoshi</given-names></name>
<xref rid="af1-MCO-16-4-02510" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Haruhara</surname><given-names>Yuki</given-names></name>
<xref rid="af1-MCO-16-4-02510" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Watanabe</surname><given-names>Kenta</given-names></name>
<xref rid="af1-MCO-16-4-02510" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nomura</surname><given-names>Keiko</given-names></name>
<xref rid="af2-MCO-16-4-02510" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kanamori</surname><given-names>Masahiko</given-names></name>
<xref rid="af3-MCO-16-4-02510" ref-type="aff">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kawaguchi</surname><given-names>Yoshiharu</given-names></name>
<xref rid="af1-MCO-16-4-02510" ref-type="aff">1</xref>
</contrib>
</contrib-group>
<aff id="af1-MCO-16-4-02510"><label>1</label>Department of Orthopedic Surgery, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan</aff>
<aff id="af2-MCO-16-4-02510"><label>2</label>Department of Pediatrics, University of Toyama, Toyama 930-0194, Japan</aff>
<aff id="af3-MCO-16-4-02510"><label>3</label>Department of Human Science 1, University of Toyama, Toyama 930-0194, Japan</aff>
<author-notes>
<corresp id="c1-MCO-16-4-02510"><italic>Correspondence to:</italic> Dr Kayo Suzuki, Department of Orthopedic Surgery, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan <email>suzukayo@med.u-toyama.ac.jp</email></corresp>
<fn><p><italic>Abbreviations:</italic> EWSR1, EWS RNA-binding protein 1; FLI1, Friend leukemia virus integration site 1; ETS, erythroblast transformation-specific; CIC, capicua transcriptional repressor; BCOR, BCL6 corepressor; RT-PCR, reverse transcription polymerase chain reaction; CCNB3, cyclin B3; MAML3, mastermind-like transcriptional coactivator 3; ZC3H7B, zinc finger CCCH domain-containing protein 7B; ITD, internal tandem duplications; ALP, alkaline phosphatase; CT, computed tomography; MRI, magnetic resonance imaging; FDG-PET, <sup>18</sup>F-fluoro-2-deoxyglucose positron emission tomography; SUV, standardized uptake value; sIL-2R, soluble interleukin 2 receptor; DUX4, double homeobox 4</p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>04</month>
<year>2022</year></pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>02</month>
<year>2022</year></pub-date>
<volume>16</volume>
<issue>4</issue>
<elocation-id>77</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>11</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>12</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Suzuki et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>BCL6 corepressor-cyclin B3 (<italic>BCOR-CCNB3</italic>) fusion sarcoma was classified as an emerging subgroup of undifferentiated small round cell sarcoma in 2020. The incidence of <italic>BCOR-CCNB3</italic> fusion sarcoma is reportedly 1.5-14&#x0025; among undifferentiated unclassified sarcomas, representing a rare entity among primary malignant bone tumors. The present study reports a case of <italic>BCOR-CCNB3</italic> fusion sarcoma in the proximal tibia of a boy. A 12-year-old boy presented with a 6-month history of knee pain and a slowly growing mass in the anteromedial aspect of the left proximal tibia. Plain radiography and computed tomography of the knee demonstrated a lytic lesion with cortical destruction of the proximal tibia. Magnetic resonance imaging showed the bone tumor expanding into soft tissue with almost homogeneous hypointensity on T1-weighted imaging and slightly hyperintensity on T2-weighted imaging. On histopathological evaluation, the tumor comprised a proliferation of small, round to ovoid-shaped mesenchymal cells without osteoid formation. Histopathologically, <italic>BCOR-CCNB3</italic> sarcoma of bone was finally diagnosed based on immunohistochemical staining and additional molecular analyses. The patient underwent bone tumor resection followed by pre- and post-operative chemotherapy according to a Ewing sarcoma protocol. The patient showed no evidence of local recurrence or distant metastasis at 12 months after completion of adjuvant chemotherapy. We present herein an additional case of <italic>BCOR-CCNB3</italic> sarcoma of the proximal tibia, and review the relevant literature on <italic>BCOR-CCNB3</italic> sarcoma of bone.</p>
</abstract>
<kwd-group>
<kwd><italic>BCOR-CCNB3</italic></kwd>
<kwd>BCOR-rearrangement sarcoma</kwd>
<kwd>RT-PCR</kwd>
<kwd>clinical characteristic</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding:</bold> This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (grant no. JP20K09497).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Undifferentiated small round cell sarcoma is a newly classified category of bone and soft tissue sarcoma according to the 2020 World Health Organization classification (<xref rid="b1-MCO-16-4-02510" ref-type="bibr">1</xref>). This newly defined category includes Ewing sarcoma and small round cell sarcoma, previously known as Ewing-like sarcoma. Ewing sarcoma is the most well-known, with the characteristic chromosomal translocation abnormality t(11;22) (q24;q12) causing fusion of the EWS RNA-binding protein 1 (<italic>EWSR1</italic>) and Friend leukemia virus integration site 1 (<italic>FLI1</italic>) genes (<xref rid="b2-MCO-16-4-02510" ref-type="bibr">2</xref>). So-called &#x2018;Ewing-like sarcoma&#x2019; is also an aggressive sarcoma comprising small round tumor cells arising from bone and soft tissue. In terms of histopathological features, Ewing-like sarcoma is morphologically similar to Ewing sarcoma, but lacks the classical fusion of <italic>EWSR1</italic> and erythroblast transformation-specific (<italic>ETS</italic>) family genes, such as <italic>FLI1</italic> (<xref rid="b1-MCO-16-4-02510" ref-type="bibr">1</xref>). According to molecular analyses over the last two decades, undifferentiated small round cell sarcoma (Ewing-like sarcoma) has been recognized to exhibit three different genetic features: capicua transcriptional repressor (<italic>CIC</italic>)-rearranged sarcoma (<xref rid="b3-MCO-16-4-02510" ref-type="bibr">3</xref>); BCL6 corepressor (<italic>BCOR</italic>)-rearranged sarcoma (<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>); and round cell sarcoma with <italic>EWSR1</italic>-non-ETS fusion (<xref rid="b5-MCO-16-4-02510" ref-type="bibr">5</xref>). Of the undifferentiated small round cell sarcomas without <italic>EWSR1-ETS</italic> gene fusion, <italic>CIC</italic>-rearrangement sarcomas account for the majority, at 60-70&#x0025; (<xref rid="b6-MCO-16-4-02510" ref-type="bibr">6</xref>). Molecular findings support these sarcoma subtypes being biologically distinct from Ewing sarcoma.</p>
<p><italic>BCOR</italic>-rearrangement sarcoma was first identified by Pierron <italic>et al</italic> in 2012 among 594 cases of undifferentiated round cell sarcoma that morphologically resembled Ewing sarcoma, but lacked the canonical <italic>EWSR1-ETS</italic> translocation (<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>). RNA sequencing and subsequent reverse transcription-polymerase chain reaction (RT-PCR) demonstrated a novel <italic>BCOR-</italic>cyclin B3 <italic>(CCNB3)</italic> fusion gene in 24 tumors (4&#x0025;), resulting from a chromosome-X paracentric inversion (<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>). This inversion causes an in-frame fusion between exon 15 of <italic>BCOR</italic> and exon 5 of <italic>CCNB3</italic>. <italic>BCOR-CCNB3</italic> fusion is the most frequent fusion seen among <italic>BCOR</italic>-rearrangement sarcomas, accounting for &#x007E;60&#x0025; (<xref rid="b7-MCO-16-4-02510" ref-type="bibr">7</xref>). <italic>BCOR</italic>-rearrangement sarcoma occurs slightly more often in bone than in soft tissue, at a ratio of 1.5:1(<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>). Other fusion partners of <italic>BCOR</italic> have recently been identified, namely mastermind-like transcriptional coactivator 3 (<italic>MAML3</italic>), zinc finger CCCH domain-containing protein 7B (<italic>ZC3H7B</italic>), and internal tandem duplications (<italic>ITD</italic>) (<xref rid="b8-MCO-16-4-02510" ref-type="bibr">8</xref>,<xref rid="b9-MCO-16-4-02510" ref-type="bibr">9</xref>). <italic>BCOR-MAML3</italic> and <italic>ZC3H7B-BCOR</italic> fusion sarcomas have been reported in a small number of tumors arising in soft tissue (<xref rid="b8-MCO-16-4-02510" ref-type="bibr">8</xref>). <italic>BCOR</italic> ITD has been reported in a subgroup of soft-tissue undifferentiated round cell sarcomas occurring in infants (<xref rid="b9-MCO-16-4-02510" ref-type="bibr">9</xref>).</p>
<p><italic>BCOR</italic>-rearrangement sarcoma of bone is gaining widespread recognition among pathologists, but remains less recognized by clinical orthopedic surgeons than osteosarcoma or Ewing sarcoma. We present herein an additional case of <italic>BCOR-CCNB3</italic> sarcoma of the proximal tibia, and review the relevant literature on <italic>BCOR-CCNB3</italic> sarcoma of bone. Our review of the literature focused on the clinical characteristics, histopathology, and prognosis of <italic>BCOR-CCNB3</italic> sarcoma arising in bone.</p>
</sec>
<sec sec-type="Case|presentation">
<title>Case presentation</title>
<p>This report was approved by the ethics committee at Toyama University Hospital (Toyama, Japan), and the patient and his parents provided written, informed consent for publication of this report. A 12-year-old boy presented with a 6-month history of knee pain on flexion of the knee joint and a slowly growing mass in the anteromedial aspect of the proximal left tibia. There was no special mention of medical history or his family history. Physical examination revealed an elastic hard mass without tenderness or redness, with mild warmth. Despite a lack of limitations to motion of the knee joint, he experienced pain on full flexion of the knee joint. Laboratory tests revealed regular leukocyte counts (6,250/&#x00B5;l). The C-reactive protein level was not elevated at 0.02 mg/dl. Although the normal range of alkaline phosphatase (ALP) in children is wide, the value of ALP was slightly high at 1,298 U/l. Other biochemical blood test was normal. Plain radiographs of the knee demonstrated an extraskeletal mass in the soft tissue at the medial aspect of the proximal tibia on anteroposterior view and a lytic lesion with cortical destruction of the proximal tibia on lateral view (<xref rid="f1-MCO-16-4-02510" ref-type="fig">Fig. 1</xref>). Computed tomography (CT) confirmed a lytic bone tumor with periosteal reaction in the proximal metaphysis of the tibia and a soft tissue tumor with extraosseous soft tissue extension (<xref rid="f2-MCO-16-4-02510" ref-type="fig">Fig. 2</xref>). Magnetic resonance imaging (MRI) showed the bone tumor expanding into soft tissue with almost homogeneous hypointensity on T1-weighted imaging and slight hyperintensity on T2-weighted imaging compared to muscle (<xref rid="f3-MCO-16-4-02510" ref-type="fig">Fig. 3</xref>). On <sup>18</sup>F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)/CT, accumulation of FDG was seen only in the bone tumor of the proximal tibia, with a maximum standardized uptake value (SUV) of 8.6 and no distant metastases. Based on these findings from images, primary malignant bone tumor was highly suspected. Differential diagnoses included osteosarcoma, Ewing sarcoma, and malignant lymphoma. Open biopsy was performed to determine the histopathological diagnosis.</p>
<p>On histopathological evaluation, the tumor comprised proliferation of the small, round to ovoid-shaped mesenchymal cells without osteoid formation (<xref rid="f4-MCO-16-4-02510" ref-type="fig">Fig. 4A</xref>). The nuclei of some tumor cells appeared hyperchromatic with finely dispersed chromatin. Immunohistochemically, tumor cells were completely negative for AE1/AE3, S-100 protein, STAT6, CD34, c-Myc, CD117 and alpha-smooth muscle actin. CD99 (clone 12E7, DAKO, 1:100) expression revealed weak membranous immunostaining (<xref rid="f4-MCO-16-4-02510" ref-type="fig">Fig. 4B</xref>), and CCNB3 (clone HPA000496; Sigma-Aldrich, 1:200) expressed strong and diffuse nuclear positivity (<xref rid="f4-MCO-16-4-02510" ref-type="fig">Fig. 4C</xref>). Considering the histopathological findings, the pathological diagnosis favored Ewing-like sarcoma rather than Ewing sarcoma. Additional molecular examination by RT-PCR were performed using formalin-fixed paraffin-embedded tissues. RT-PCR detected a <italic>BCOR-CCNB3</italic> fusion transcript rather than <italic>CIC-</italic>double homeobox 4 (<italic>DUX4</italic>). Additional direct Sanger sequencing using PCR product revealed a <italic>BCOR-CCNB3</italic> fusion (<xref rid="f5-MCO-16-4-02510" ref-type="fig">Fig. 5</xref>). The patient received 2.5 cycles of neoadjuvant chemotherapy according to a Ewing sarcoma protocol (<xref rid="b10-MCO-16-4-02510" ref-type="bibr">10</xref>), using vincristine (1.5 mg/m<sup>2</sup>), doxorubicin (75 mg/m<sup>2</sup>), and cyclophosphamide (1,200 mg/m<sup>2</sup>) alternating with ifosfamide (1,800 mg/m<sup>2</sup>) and etoposide (100 mg/m<sup>2</sup>). On evaluation of the effect of neoadjuvant chemotherapy, MRI showed a reduction in the size of the tumor, which had extraskeletal extension into soft tissue, by &#x007E;20&#x0025;. FDG-PET/CT showed a decrease in maximum SUV from 8.6 to 2.5 (<xref rid="f6-MCO-16-4-02510" ref-type="fig">Fig. 6</xref>). Although there was little reduction in tumor size, the activity of tumor cells was judged to be attenuated. Following neoadjuvant chemotherapy, the patient underwent surgery. The surgery comprised wide resection of the bone tumor of the proximal tibia and endoprosthetic reconstruction with a mega-prosthesis. The remaining patellar tendon was sutured to the holes on the proximal tibia prosthesis with a multi-strand sutures made by ultra-high molecular weight polyethylene. Then, the extensor mechanism of the knee joint was reconstructed by the gastrocnemius muscle transfer using the quadriceps tendon and iliotibial band reported by Yoshida <italic>et al</italic> (<xref rid="b11-MCO-16-4-02510" ref-type="bibr">11</xref>). Specimens of resected bone tumor contained less than 10&#x0025; viable tumor cells and were evaluated as showing good chemosensitivity to neoadjuvant chemotherapy. Postoperatively, the patient received an additional 3.5 cycles of adjuvant chemotherapy with vincristine (1.5 mg/m<sup>2</sup>), doxorubicin (75 mg/m<sup>2</sup>) or actinomycin-D (0.045 mg/kg), and cyclophosphamide (1,200 mg/m<sup>2</sup>) alternating with ifosfamide (1,800 mg/m<sup>2</sup>) and etoposide (100 mg/m<sup>2</sup>). Severe adverse event during chemotherapy was white blood cell decreased corresponding to Grade 4 by Common Terminology Criteria for Adverse Events (Version 5.0). The patient developed a neutropenia rated Grade 4 and received granulocyte-colony stimulating factor. Grade 3 anemia was treated with blood transfusion. The patient completed the chemotherapy regimen as planned, with no sequelae. The patient showed no evidence of local recurrence or distant metastasis at 12 months after completion of adjuvant chemotherapy. The range of motion in his knee joint was 0-125 degrees without extension lag, and he was able to walk without a cane. Functional outcome was calculated with musculoskeletal society tumor score with the result of 90&#x0025;.</p>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p><italic>BCOR-CCNB3</italic> fusion sarcoma was first identified by Pierron <italic>et al</italic> (<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>) in 2012 and was classified to the emerging subgroup of undifferentiated small round cell sarcomas in 2020(<xref rid="b1-MCO-16-4-02510" ref-type="bibr">1</xref>). However, due to the newly established entity of sarcoma, a number of recent studies on <italic>BCOR-CCNB3</italic> have been re-diagnosed using molecular and genetic techniques from tumors previously diagnosed as undifferentiated sarcoma. This sarcoma remains a tumor that orthopedic surgeons rarely encounter. To clarify the clinical characteristics of the emerging subset of bone sarcomas with <italic>BCOR-CCNB3</italic> fusion, we evaluated a total of 72 cases of <italic>BCOR-CCNB3</italic> sarcoma of bone reported between 2012 and 2021 (including the present case), where at least the location of the affected bone or outcome at final follow-up was described (<xref rid="tI-MCO-16-4-02510" ref-type="table">Table I</xref>) (<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>,<xref rid="b12-MCO-16-4-02510 b13-MCO-16-4-02510 b14-MCO-16-4-02510 b15-MCO-16-4-02510 b16-MCO-16-4-02510 b17-MCO-16-4-02510 b18-MCO-16-4-02510 b19-MCO-16-4-02510 b20-MCO-16-4-02510 b21-MCO-16-4-02510 b22-MCO-16-4-02510" ref-type="bibr">12-22</xref>). The incidence of <italic>BCOR-CCNB3</italic> fusion sarcoma is reportedly 1.5-14&#x0025; among undifferentiated unclassified sarcomas (<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>,<xref rid="b14-MCO-16-4-02510" ref-type="bibr">14</xref>,<xref rid="b16-MCO-16-4-02510" ref-type="bibr">16</xref>). <italic>BCOR-CCNB3</italic> sarcoma of bone shows a striking predilection for children, with over 90&#x0025; of patients diagnosed at under 20 years old. The mean age of cases for which age was described was 13.8 years (range, 2-25 years), similar to the cited peak incidence between 5 and 20 years old for the Ewing sarcoma family of tumors (<xref rid="b23-MCO-16-4-02510" ref-type="bibr">23</xref>). Evaluating 70 cases with descriptions of sex, males are affected more frequently, with a male-to-female ratio of 6.7:1 (<xref rid="b4-MCO-16-4-02510" ref-type="bibr">4</xref>,<xref rid="b12-MCO-16-4-02510 b13-MCO-16-4-02510 b14-MCO-16-4-02510 b15-MCO-16-4-02510 b16-MCO-16-4-02510 b17-MCO-16-4-02510 b18-MCO-16-4-02510 b19-MCO-16-4-02510 b20-MCO-16-4-02510 b21-MCO-16-4-02510 b22-MCO-16-4-02510" ref-type="bibr">12-22</xref>). The bone sites involved are most often a long bone of the limbs (n=28, 38.9&#x0025;), followed by the pelvis (n=27, 37.5&#x0025;), calcaneus (n=7, 9.7&#x0025;), and spine (n=6, 8.3&#x0025;). Among the long bone of limbs, the most common location is the femur (n=13), followed by the tibia (n=10) and fibula (n=4). <italic>BCOR-CCNB3</italic> sarcoma of bone often arises in the metaphyseal-diaphyseal portion of the femur or tibia (<xref rid="b12-MCO-16-4-02510" ref-type="bibr">12</xref>). These more common locations of <italic>BCOR-CCNB3</italic> sarcoma of bone are similar to those reported for skeletal Ewing sarcoma (<xref rid="b24-MCO-16-4-02510" ref-type="bibr">24</xref>).</p>
<p>Imaging features of <italic>BCOR-CCNB3</italic> sarcoma of bone resemble those of aggressive malignant bone tumors such as Ewing sarcoma. Due to the relatively small number of cases reported and the frequency of case series lacking imaging findings, radiological imaging characteristics for <italic>BCOR-CCNB3</italic> sarcoma of bone are difficult to summarize. However, a recent case series and literature review by Brady <italic>et al</italic> and a review article by Sirisena <italic>et al</italic> have reported detailed features of imaging (<xref rid="b22-MCO-16-4-02510" ref-type="bibr">22</xref>,<xref rid="b25-MCO-16-4-02510" ref-type="bibr">25</xref>). The most common radiological features were bone lysis, seen in 60&#x0025;, mixed lysis and sclerosis in 25&#x0025;, and sclerotic changes in 15&#x0025;. Periosteal reactions were relatively common in long bones, but to varying degrees (<xref rid="b12-MCO-16-4-02510" ref-type="bibr">12</xref>,<xref rid="b22-MCO-16-4-02510" ref-type="bibr">22</xref>). In the present case, radiography showed a lytic lesion with a moth-eaten appearance as a weak periosteal reaction; this may be because bone tumors tend to develop around sites of Osgood-Schlatter disease. The contralateral proximal tibia showed Osgood-Schlatter disease (data not shown). Based on the MRI findings reviewed by Sirisena <italic>et al</italic>, <italic>BCOR-CCNB3</italic> sarcoma of bone commonly demonstrated intermediate signal intensity on T1-weighted imaging and heterogeneous increased on T2-weighted signal intensity (<xref rid="b25-MCO-16-4-02510" ref-type="bibr">25</xref>). Furthermore, a common MRI finding for some <italic>BCOR-CCNB3</italic> sarcomas of bone, as well in the present case, is the presence of tumor showing extraosseous soft-tissue extension (<xref rid="b25-MCO-16-4-02510" ref-type="bibr">25</xref>). On MRI, the finding of extraosseous soft tissue extension is similar to that of Ewing sarcoma (<xref rid="b26-MCO-16-4-02510" ref-type="bibr">26</xref>), making that pathology difficult to distinguish from <italic>BCOR-CCNB3</italic> sarcoma of bone. However, T2-weighted MRI of Ewing sarcoma typically shows homogeneous intensity, reflecting the proliferation of small, round, blue tumor cells (<xref rid="b26-MCO-16-4-02510" ref-type="bibr">26</xref>). Another differential diagnosis from the present case on the imaging findings is primary bone lymphoma and osteosarcoma. However, primary bone lymphoma shows a predilection for the fourth to sixth decades (<xref rid="b27-MCO-16-4-02510" ref-type="bibr">27</xref>). Moreover, distinguishing points between primary bone lymphoma and <italic>BCOR-CCNB3</italic> sarcoma of bone are the level of soluble interleukin 2 receptor (sIL-2R) in serum. Akahane <italic>et al</italic> reported that sIL-2R showed 95&#x0025; sensitivity and 70&#x0025; specificity for primary bone lymphoma, making this marker useful for differentiating from other primary bone tumors (<xref rid="b28-MCO-16-4-02510" ref-type="bibr">28</xref>). Osteosarcoma is the most common primary malignant bone tumor in the first to second decades of life. Among osteosarcomas, small cell osteosarcoma occasionally presents with radiological findings similar to those of Ewing sarcoma, showing a predominantly lytic, non-mineralized appearance on radiography (<xref rid="b29-MCO-16-4-02510" ref-type="bibr">29</xref>). On MRI, small cell osteosarcoma appears as typically iso- to hypointense homogeneous lesions on T1-weighted imaging and hyperintense heterogeneous lesions on T2-weighted imaging compared to muscle (<xref rid="b30-MCO-16-4-02510" ref-type="bibr">30</xref>), and these findings resembles <italic>BCOR-CCNB3</italic> of bone.</p>
<p>Histopathological features of <italic>BCOR-CCNB3</italic> sarcoma of bone typically present a tumor comprising a uniform proliferation of short, spindle-shaped to round cells with scant cytoplasm and irregular nuclei (<xref rid="b17-MCO-16-4-02510" ref-type="bibr">17</xref>). Compared to typical Ewing sarcoma, tumor cells from <italic>BCOR-CCNB3</italic> sarcoma of bone are more likely to be spindle-shaped. Some cases of <italic>BCOR-CCNB3</italic> sarcoma reportedly show variations in cellularity and myxoid changes to the stroma (<xref rid="b5-MCO-16-4-02510" ref-type="bibr">5</xref>,<xref rid="b17-MCO-16-4-02510" ref-type="bibr">17</xref>). Differential diagnoses for <italic>BCOR-CCNB3</italic> sarcoma of bone include Ewing sarcoma, <italic>CIC</italic>-rearrangement sarcoma, so-called Ewing-like sarcoma, and small round cell osteosarcoma. Several reports have shown the specificity of simple CCNB3 immunohistochemical staining for <italic>BCOR-CCNB3</italic> sarcoma, which is not found in Ewing sarcoma or <italic>CIC</italic>-rearranged sarcoma. Most <italic>BCOR-CCNB3</italic> sarcomas exhibit strong, diffuse positivity for CCNB3 with a nuclear positivity (<xref rid="b12-MCO-16-4-02510" ref-type="bibr">12</xref>,<xref rid="b13-MCO-16-4-02510" ref-type="bibr">13</xref>,<xref rid="b15-MCO-16-4-02510" ref-type="bibr">15</xref>). In addition, the pattern of CD99 immunohistochemical staining may also prove helpful to distinguish this tumor from Ewing sarcoma. Where typical CD99 staining in Ewing sarcoma shows a diffusely membranous positive pattern in almost all cases, patchy, weakly positive staining for CD99 is seen in &#x007E;70&#x0025; of <italic>BCOR-CCNB3</italic> sarcomas (<xref rid="b13-MCO-16-4-02510" ref-type="bibr">13</xref>). Our case of <italic>BCOR-CCNB3</italic> sarcoma of the tibia showed strong, diffuse positivity for CCNB3, including nuclear positivity, and weak positivity for CD99. A combination of morphological, immunohistochemical, and molecular findings allows accurate classification in most cases.</p>
<p>Although <italic>BCOR-CCNB3</italic> sarcoma of bone is molecularly distinct from Ewing sarcoma, the clinical behaviors, radiological features, and histopathological morphology show some similarities with Ewing sarcoma. To date, multidisciplinary treatment combining chemotherapy and surgery for Ewing sarcoma has been established as standard. For the treatment of <italic>BCOR-CCNB3</italic> sarcoma of bone, neoadjuvant chemotherapy followed by surgery and postoperative adjuvant chemotherapy, representing the same protocol applied for Ewing sarcoma, has also been proposed (<xref rid="b12-MCO-16-4-02510" ref-type="bibr">12</xref>). When we reviewed the case series of <italic>BCOR-CCNB3</italic> sarcoma of bone (<xref rid="tI-MCO-16-4-02510" ref-type="table">Table I</xref>), 33 of the 72 cases had received chemotherapy based on the standard treatment for Ewing sarcoma. Our present case had also received neoadjuvant and adjuvant chemotherapy based on the regimen for Ewing sarcoma, and our patient showed no evidence of local recurrence or distant metastasis as of 1 year after completing adjuvant chemotherapy. In patients with localized <italic>BCOR-CCNB3</italic> sarcoma of bone and soft tissue, the overall survival rate at 5 years is reportedly significantly better for patients who have received treatment according to the Ewing protocol than for those who have received other chemotherapeutic regimens (<xref rid="b12-MCO-16-4-02510" ref-type="bibr">12</xref>). Previous reports have stated that the 5-year overall survival rate for <italic>BCOR-CCNB3</italic> sarcoma ranges from 72 to 76.5&#x0025; (<xref rid="b12-MCO-16-4-02510" ref-type="bibr">12</xref>,<xref rid="b13-MCO-16-4-02510" ref-type="bibr">13</xref>,<xref rid="b20-MCO-16-4-02510" ref-type="bibr">20</xref>).</p>
<p>The patient and his parents were satisfied with the favorable oncological results of the treatment according to Ewing sarcoma. The postoperative function of the affected limb is also good, and the patient is able to walk stably without a cane.</p>
<p>We reported a case of <italic>BCOR-CCNB3</italic> sarcoma arising in the proximal tibia and reviewed the literature for <italic>BCOR-CCNB3</italic> sarcoma of bone in terms of clinical features, therapy and prognosis. <italic>BCOR-CCNB3</italic> sarcoma requires differentiation from Ewing sarcoma and small cell osteosarcoma using diagnostic imaging, given the histopathological similarity with Ewing sarcoma. Patchy, weakly positive immunohistochemical staining for CD99 and strong, diffusely positive staining for CCNB3 are useful for diagnosing <italic>BCOR-CCNB3</italic> sarcoma. Confirmation of the <italic>BCOR-CCNB3</italic> fusion gene by RT-PCR is necessary for final definitive diagnosis. The prognosis of <italic>BCOR-CCNB3</italic> sarcoma is expected to be relatively good with the introduction of multidisciplinary treatment according to the protocol for Ewing sarcoma at an early stage.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors are grateful to Akira Noguchi and Professor Joji Imura, Department of Pathology, University of Toyama (Toyama, Japan), for discussion of histopathological diagnosis.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>KS and YH made substantial contributions to the conception and design. TY was responsible for the acquisition or analysis and interpretation of data. KW acquired clinical imaging data. KS, TY and KW were involved in surgical treatment. KN was mainly in charge of neoadjuvant and adjuvant chemotherapy. MK and YK critically analyzed and interpreted the data. KS made a critical revision of the article for important intellectual content. KS and TY confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>This report was approved by the Ethics Committee of the Toyama University Hospital (Toyama, Japan; approval no. &#x2018;21-22&#x2019;).</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Written informed consent was obtained from the patient for publication of this report and accompanying images. A copy of the written consent is available for review upon request.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-MCO-16-4-02510"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridge</surname><given-names>JA</given-names></name></person-group><comment>Undifferentiated small round cell sarcomas of bone and soft tissue. In: WHO classification of tumours of soft tissue and bone tumours. IARC Press, Lyon, pp326-335, 2020.</comment></element-citation></ref>
<ref id="b2-MCO-16-4-02510"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turc-Carel</surname><given-names>C</given-names></name><name><surname>Aurias</surname><given-names>A</given-names></name><name><surname>Mugneret</surname><given-names>F</given-names></name><name><surname>Lizard</surname><given-names>S</given-names></name><name><surname>Sidaner</surname><given-names>I</given-names></name><name><surname>Volk</surname><given-names>C</given-names></name><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Olschwang</surname><given-names>S</given-names></name><name><surname>Philip</surname><given-names>I</given-names></name><name><surname>Berger</surname><given-names>MP</given-names></name></person-group><article-title>Chromosomes in Ewing&#x0027;s sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12)</article-title><source>Cancer Genet Cytogenet</source><volume>32</volume><fpage>229</fpage><lpage>238</lpage><year>1988</year><pub-id pub-id-type="pmid">3163261</pub-id><pub-id pub-id-type="doi">10.1016/0165-4608(88)90285-3</pub-id></element-citation></ref>
<ref id="b3-MCO-16-4-02510"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura-Saito</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Kawaguchi</surname><given-names>N</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Mukai</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>T</given-names></name><name><surname>Motoi</surname><given-names>T</given-names></name><name><surname>Fukayama</surname><given-names>M</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><etal/></person-group><article-title>Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation</article-title><source>Hum Mol Genet</source><volume>15</volume><fpage>2125</fpage><lpage>2137</lpage><year>2006</year><pub-id pub-id-type="pmid">16717057</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddl136</pub-id></element-citation></ref>
<ref id="b4-MCO-16-4-02510"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierron</surname><given-names>G</given-names></name><name><surname>Tirode</surname><given-names>F</given-names></name><name><surname>Lucchesi</surname><given-names>C</given-names></name><name><surname>Reynaud</surname><given-names>S</given-names></name><name><surname>Ballet</surname><given-names>S</given-names></name><name><surname>Cohen-Gogo</surname><given-names>S</given-names></name><name><surname>Perrin</surname><given-names>V</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name></person-group><article-title>A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion</article-title><source>Nat Genet</source><volume>44</volume><fpage>461</fpage><lpage>466</lpage><year>2012</year><pub-id pub-id-type="pmid">22387997</pub-id><pub-id pub-id-type="doi">10.1038/ng.1107</pub-id></element-citation></ref>
<ref id="b5-MCO-16-4-02510"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sbaraglia</surname><given-names>M</given-names></name><name><surname>Righi</surname><given-names>A</given-names></name><name><surname>Gambarotti</surname><given-names>M</given-names></name><name><surname>Dei Tos</surname><given-names>AP</given-names></name></person-group><article-title>Ewing sarcoma and Ewing-like tumors</article-title><source>Virchows Arch</source><volume>476</volume><fpage>109</fpage><lpage>119</lpage><year>2020</year><pub-id pub-id-type="pmid">31802230</pub-id><pub-id pub-id-type="doi">10.1007/s00428-019-02720-8</pub-id></element-citation></ref>
<ref id="b6-MCO-16-4-02510"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonescu</surname><given-names>C</given-names></name></person-group><article-title>Round cell sarcomas beyond Ewing: Emerging entities</article-title><source>Histopathology</source><volume>64</volume><fpage>26</fpage><lpage>37</lpage><year>2014</year><pub-id pub-id-type="pmid">24215322</pub-id><pub-id pub-id-type="doi">10.1111/his.12281</pub-id></element-citation></ref>
<ref id="b7-MCO-16-4-02510"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Loarer</surname><given-names>F</given-names></name><name><surname>Pissaloux</surname><given-names>D</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name><name><surname>Tirode</surname><given-names>F</given-names></name><name><surname>Vince</surname><given-names>DR</given-names></name></person-group><article-title>Update on families of round cell sarcomas other than classical Ewing sarcomas</article-title><source>Surg Pathol Clin</source><volume>10</volume><fpage>587</fpage><lpage>620</lpage><year>2017</year><pub-id pub-id-type="pmid">28797504</pub-id><pub-id pub-id-type="doi">10.1016/j.path.2017.04.002</pub-id></element-citation></ref>
<ref id="b8-MCO-16-4-02510"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Specht</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sung</surname><given-names>YS</given-names></name><name><surname>Nucci</surname><given-names>M</given-names></name><name><surname>Dry</surname><given-names>S</given-names></name><name><surname>Vaiyapuri</surname><given-names>S</given-names></name><name><surname>Richter</surname><given-names>GH</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name></person-group><article-title>Novel BCOR-MAML3 and ZC3H7B-BCOR gene fusions in undifferentiated small blue round cell sarcomas</article-title><source>Am J Surg Pathol</source><volume>40</volume><fpage>433</fpage><lpage>442</lpage><year>2016</year><pub-id pub-id-type="pmid">26752546</pub-id><pub-id pub-id-type="doi">10.1097/PAS.0000000000000591</pub-id></element-citation></ref>
<ref id="b9-MCO-16-4-02510"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>YC</given-names></name><name><surname>Sung</surname><given-names>YS</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Argani</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>CT</given-names></name><name><surname>Graf</surname><given-names>NS</given-names></name><name><surname>Wright</surname><given-names>DC</given-names></name><name><surname>Kellie</surname><given-names>SJ</given-names></name><name><surname>Agaram</surname><given-names>NP</given-names></name><etal/></person-group><article-title>Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B fusions in soft tissue undifferentiated round cell sarcoma of infancy: Overlapping genetic features with clear cell sarcoma of kidney</article-title><source>Am J Surg Pathol</source><volume>40</volume><fpage>1009</fpage><lpage>1020</lpage><year>2016</year><pub-id pub-id-type="pmid">26945340</pub-id><pub-id pub-id-type="doi">10.1097/PAS.0000000000000629</pub-id></element-citation></ref>
<ref id="b10-MCO-16-4-02510"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grier</surname><given-names>HE</given-names></name><name><surname>Krailo</surname><given-names>MD</given-names></name><name><surname>Tarbell</surname><given-names>NJ</given-names></name><name><surname>Link</surname><given-names>MP</given-names></name><name><surname>Fryer</surname><given-names>CJ</given-names></name><name><surname>Pritchard</surname><given-names>DJ</given-names></name><name><surname>Gebhardt</surname><given-names>MC</given-names></name><name><surname>Dickman</surname><given-names>PS</given-names></name><name><surname>Perlman</surname><given-names>EJ</given-names></name><name><surname>Meyers</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Addition of ifosfamide and etoposide to standard chemotherapy for Ewing&#x0027;s sarcoma and primitive neuroectodermal tumor of bone</article-title><source>N Engl J Med</source><volume>348</volume><fpage>694</fpage><lpage>701</lpage><year>2003</year><pub-id pub-id-type="pmid">12594313</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa020890</pub-id></element-citation></ref>
<ref id="b11-MCO-16-4-02510"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Osaka</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>J</given-names></name></person-group><article-title>Reconstruction of the knee extensor mechanism in patients with a malignant bone tumor of the proximal tibia</article-title><source>Surg Today</source><volume>40</volume><fpage>646</fpage><lpage>649</lpage><year>2010</year><pub-id pub-id-type="pmid">20582516</pub-id><pub-id pub-id-type="doi">10.1007/s00595-009-4161-z</pub-id></element-citation></ref>
<ref id="b12-MCO-16-4-02510"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen-Gogo</surname><given-names>S</given-names></name><name><surname>Cellier</surname><given-names>C</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name><name><surname>Mosseri</surname><given-names>V</given-names></name><name><surname>Pierron</surname><given-names>G</given-names></name><name><surname>Guillemet</surname><given-names>C</given-names></name><name><surname>Italiano</surname><given-names>A</given-names></name><name><surname>Brugi&#x00E8;res</surname><given-names>L</given-names></name><name><surname>Orbach</surname><given-names>D</given-names></name><name><surname>Laurence</surname><given-names>V</given-names></name><etal/></person-group><article-title>Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: A clinical, radiological and pathological retrospective study from the Soci&#x00E9;t&#x00E9; Fran&#x00E7;aise des Cancers de L&#x0027;Enfant</article-title><source>Pediatr Blood Cancer</source><volume>61</volume><fpage>2191</fpage><lpage>2198</lpage><year>2014</year><pub-id pub-id-type="pmid">25176412</pub-id><pub-id pub-id-type="doi">10.1002/pbc.25210</pub-id></element-citation></ref>
<ref id="b13-MCO-16-4-02510"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puls</surname><given-names>F</given-names></name><name><surname>Niblett</surname><given-names>A</given-names></name><name><surname>Marland</surname><given-names>G</given-names></name><name><surname>Gaston</surname><given-names>CL</given-names></name><name><surname>Douis</surname><given-names>H</given-names></name><name><surname>Mangham</surname><given-names>DC</given-names></name><name><surname>Sumathi</surname><given-names>VP</given-names></name><name><surname>Kindblom</surname><given-names>LG</given-names></name></person-group><article-title>BCOR-CCNB3 (Ewing-like) sarcoma: A clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma</article-title><source>Am J Surg Pathol</source><volume>38</volume><fpage>1307</fpage><lpage>1318</lpage><year>2014</year><pub-id pub-id-type="pmid">24805859</pub-id><pub-id pub-id-type="doi">10.1097/PAS.0000000000000223</pub-id></element-citation></ref>
<ref id="b14-MCO-16-4-02510"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>TL</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Polikepahad</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>FY</given-names></name><name><surname>Sarabia</surname><given-names>SF</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Doddapaneni</surname><given-names>H</given-names></name><name><surname>Chao</surname><given-names>H</given-names></name><etal/></person-group><article-title>BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children</article-title><source>Mod Pathol</source><volume>28</volume><fpage>575</fpage><lpage>586</lpage><year>2015</year><pub-id pub-id-type="pmid">25360585</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.2014.139</pub-id></element-citation></ref>
<ref id="b15-MCO-16-4-02510"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibayama</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Minamiguchi</surname><given-names>S</given-names></name><name><surname>Kataoka</surname><given-names>TR</given-names></name><name><surname>Shibuya</surname><given-names>S</given-names></name><name><surname>Yoshizawa</surname><given-names>A</given-names></name><name><surname>Toguchida</surname><given-names>J</given-names></name><name><surname>Haga</surname><given-names>H</given-names></name></person-group><article-title>Screening of BCOR-CCNB3 sarcoma using immunohistochemistry for CCNB3: A clinicopathological report of three pediatric cases</article-title><source>Pathol Int</source><volume>65</volume><fpage>410</fpage><lpage>414</lpage><year>2015</year><pub-id pub-id-type="pmid">26037154</pub-id><pub-id pub-id-type="doi">10.1111/pin.12319</pub-id></element-citation></ref>
<ref id="b16-MCO-16-4-02510"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>K</given-names></name><name><surname>Alaggio</surname><given-names>R</given-names></name><name><surname>Zin</surname><given-names>A</given-names></name><name><surname>Peron</surname><given-names>M</given-names></name><name><surname>Guzzardo</surname><given-names>V</given-names></name><name><surname>Benini</surname><given-names>S</given-names></name><name><surname>Righi</surname><given-names>A</given-names></name><name><surname>Gambarotti</surname><given-names>M</given-names></name></person-group><article-title>BCOR-CCNB3 undifferentiated sarcoma-does immunohistochemistry help in the identification?</article-title><source>Pediatr Dev Pathol</source><volume>20</volume><fpage>321</fpage><lpage>329</lpage><year>2017</year><pub-id pub-id-type="pmid">28420319</pub-id><pub-id pub-id-type="doi">10.1177/1093526617698263</pub-id></element-citation></ref>
<ref id="b17-MCO-16-4-02510"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Kuda</surname><given-names>M</given-names></name><name><surname>Kohashi</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Takemoto</surname><given-names>J</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Iura</surname><given-names>K</given-names></name><name><surname>Maekawa</surname><given-names>A</given-names></name><name><surname>Bekki</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><etal/></person-group><article-title>Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes</article-title><source>Virchows Arch</source><volume>470</volume><fpage>373</fpage><lpage>380</lpage><year>2017</year><pub-id pub-id-type="pmid">28197724</pub-id><pub-id pub-id-type="doi">10.1007/s00428-017-2072-8</pub-id></element-citation></ref>
<ref id="b18-MCO-16-4-02510"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>A</given-names></name><name><surname>Shiba</surname><given-names>E</given-names></name><name><surname>Umekita</surname><given-names>Y</given-names></name><name><surname>Nosaka</surname><given-names>K</given-names></name><name><surname>Kamio</surname><given-names>T</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Miyasaka</surname><given-names>C</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Ito</surname><given-names>I</given-names></name><name><surname>Tamaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinicopathologic diversity of undifferentiated sarcoma with BCOR-CCNB3 fusion: Analysis of 11 cases with a reappraisal of the utility of immunohistochemistry for BCOR and CCNB3</article-title><source>Am J Surg Pathol</source><volume>41</volume><fpage>1713</fpage><lpage>1721</lpage><year>2017</year><pub-id pub-id-type="pmid">28877060</pub-id><pub-id pub-id-type="doi">10.1097/PAS.0000000000000934</pub-id></element-citation></ref>
<ref id="b19-MCO-16-4-02510"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krskova</surname><given-names>L</given-names></name><name><surname>Kabickova</surname><given-names>E</given-names></name><name><surname>Drahokoupilova</surname><given-names>E</given-names></name><name><surname>Kopeckova</surname><given-names>K</given-names></name><name><surname>Plank</surname><given-names>L</given-names></name><name><surname>Vitkova</surname><given-names>P</given-names></name><name><surname>Mrhalova</surname><given-names>M</given-names></name><name><surname>Zamecnik</surname><given-names>J</given-names></name><name><surname>Kodet</surname><given-names>R</given-names></name></person-group><article-title>An undifferentiated sarcoma with BCOR-CCNB3 fusion transcript-pathological and clinical retrospective study</article-title><source>Neoplasma</source><volume>65</volume><fpage>630</fpage><lpage>636</lpage><year>2018</year><pub-id pub-id-type="pmid">30064235</pub-id><pub-id pub-id-type="doi">10.4149/neo_2018_171107N716</pub-id></element-citation></ref>
<ref id="b20-MCO-16-4-02510"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>YC</given-names></name><name><surname>Owosho</surname><given-names>AA</given-names></name><name><surname>Sung</surname><given-names>YS</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fujisawa</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Wexler</surname><given-names>L</given-names></name><name><surname>Argani</surname><given-names>P</given-names></name><name><surname>Swanson</surname><given-names>D</given-names></name><name><surname>Dickson</surname><given-names>BC</given-names></name><etal/></person-group><article-title>BCOR-CCNB3 fusion positive sarcomas: A clinicopathologic and molecular analysis of 36 cases with comparison to morphologic spectrum and clinical behavior of other round cell sarcomas</article-title><source>Am J Surg Pathol</source><volume>42</volume><fpage>604</fpage><lpage>615</lpage><year>2018</year><pub-id pub-id-type="pmid">29300189</pub-id><pub-id pub-id-type="doi">10.1097/PAS.0000000000000965</pub-id></element-citation></ref>
<ref id="b21-MCO-16-4-02510"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rekhi</surname><given-names>B</given-names></name><name><surname>Kembhavi</surname><given-names>P</given-names></name><name><surname>Mishra</surname><given-names>SN</given-names></name><name><surname>Shetty</surname><given-names>O</given-names></name><name><surname>Bajpai</surname><given-names>J</given-names></name><name><surname>Puri</surname><given-names>A</given-names></name></person-group><article-title>Clinicopathologic features of undifferentiated round cell sarcomas of bone &#x0026; soft tissues: An attempt to unravel the <italic>BCOR-CCNB3-</italic> &#x0026; <italic>CIC-DUX4</italic>-positive sarcomas</article-title><source>Indian J Med Res</source><volume>150</volume><fpage>557</fpage><lpage>574</lpage><year>2019</year><pub-id pub-id-type="pmid">32048619</pub-id><pub-id pub-id-type="doi">10.4103/ijmr.IJMR_2144_18</pub-id></element-citation></ref>
<ref id="b22-MCO-16-4-02510"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>EJ</given-names></name><name><surname>Hameed</surname><given-names>M</given-names></name><name><surname>Tap</surname><given-names>WD</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name></person-group><article-title>Imaging features and clinical course of undifferentiated round cell sarcomas with CIC-DUX4 and BCOR-CCNB3 translocations</article-title><source>Skeletal Radiol</source><volume>50</volume><fpage>521</fpage><lpage>529</lpage><year>2021</year><pub-id pub-id-type="pmid">32840647</pub-id><pub-id pub-id-type="doi">10.1007/s00256-020-03589-4</pub-id></element-citation></ref>
<ref id="b23-MCO-16-4-02510"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>JD</given-names></name></person-group><article-title>Ewing sarcoma family of tumors</article-title><source>Adv Anat Pathol</source><volume>12</volume><fpage>212</fpage><lpage>220</lpage><year>2005</year><pub-id pub-id-type="pmid">16096383</pub-id><pub-id pub-id-type="doi">10.1097/01.pap.0000175114.55541.52</pub-id></element-citation></ref>
<ref id="b24-MCO-16-4-02510"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mar</surname><given-names>WA</given-names></name><name><surname>Taljanovic</surname><given-names>MS</given-names></name><name><surname>Bagatell</surname><given-names>R</given-names></name><name><surname>Graham</surname><given-names>AR</given-names></name><name><surname>Speer</surname><given-names>DP</given-names></name><name><surname>Hunter</surname><given-names>TB</given-names></name><name><surname>Rogers</surname><given-names>LF</given-names></name></person-group><article-title>Update on imaging and treatment of Ewing sarcoma family tumors: What the radiologist needs to know</article-title><source>J Comput Assist Tomogr</source><volume>32</volume><fpage>108</fpage><lpage>118</lpage><year>2008</year><pub-id pub-id-type="pmid">18303298</pub-id><pub-id pub-id-type="doi">10.1097/RCT.0b013e31805c030f</pub-id></element-citation></ref>
<ref id="b25-MCO-16-4-02510"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirisena</surname><given-names>UDN</given-names></name><name><surname>Rajakulasingam</surname><given-names>R</given-names></name><name><surname>Saifuddin</surname><given-names>A</given-names></name></person-group><article-title>Imaging of bone and soft tissue BCOR-rearranged sarcoma</article-title><source>Skeletal Radiol</source><volume>50</volume><fpage>1291</fpage><lpage>1301</lpage><year>2021</year><pub-id pub-id-type="pmid">33388948</pub-id><pub-id pub-id-type="doi">10.1007/s00256-020-03683-7</pub-id></element-citation></ref>
<ref id="b26-MCO-16-4-02510"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphey</surname><given-names>MD</given-names></name><name><surname>Senchak</surname><given-names>LT</given-names></name><name><surname>Mambalam</surname><given-names>PK</given-names></name><name><surname>Logie</surname><given-names>CI</given-names></name><name><surname>Klassen-Fischer</surname><given-names>MK</given-names></name><name><surname>Kransdorf</surname><given-names>MJ</given-names></name></person-group><article-title>From the radiologic pathology archives: Ewing sarcoma family of tumors: Radiologic-pathologic correlation</article-title><source>Radiographics</source><volume>33</volume><fpage>803</fpage><lpage>831</lpage><year>2013</year><pub-id pub-id-type="pmid">23674776</pub-id><pub-id pub-id-type="doi">10.1148/rg.333135005</pub-id></element-citation></ref>
<ref id="b27-MCO-16-4-02510"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limb</surname><given-names>D</given-names></name><name><surname>Dreghorn</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>JK</given-names></name><name><surname>Mannion</surname><given-names>R</given-names></name></person-group><article-title>Primary lymphoma of bone</article-title><source>Int Orthop</source><volume>18</volume><fpage>180</fpage><lpage>183</lpage><year>1994</year><pub-id pub-id-type="pmid">7927969</pub-id><pub-id pub-id-type="doi">10.1007/BF00192476</pub-id></element-citation></ref>
<ref id="b28-MCO-16-4-02510"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akahane</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Isobe</surname><given-names>K</given-names></name><name><surname>Yoshimura</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name></person-group><article-title>Serum soluble interleukin-2 receptor levels in patients with malignant lymphoma of bone</article-title><source>J Orthop Sci</source><volume>14</volume><fpage>248</fpage><lpage>252</lpage><year>2009</year><pub-id pub-id-type="pmid">19499289</pub-id><pub-id pub-id-type="doi">10.1007/s00776-009-1335-x</pub-id></element-citation></ref>
<ref id="b29-MCO-16-4-02510"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarmish</surname><given-names>G</given-names></name><name><surname>Klein</surname><given-names>MJ</given-names></name><name><surname>Landa</surname><given-names>J</given-names></name><name><surname>Lefkowitz</surname><given-names>RA</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name></person-group><article-title>Imaging characteristics of primary osteosarcoma: Nonconventional subtypes</article-title><source>Radiographics</source><volume>30</volume><fpage>1653</fpage><lpage>1672</lpage><year>2010</year><pub-id pub-id-type="pmid">21071381</pub-id><pub-id pub-id-type="doi">10.1148/rg.306105524</pub-id></element-citation></ref>
<ref id="b30-MCO-16-4-02510"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Si</surname><given-names>L</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Jiao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name></person-group><article-title>Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature</article-title><source>J Bone Oncol</source><volume>24</volume><issue>100305</issue><year>2020</year><pub-id pub-id-type="pmid">32775179</pub-id><pub-id pub-id-type="doi">10.1016/j.jbo.2020.100305</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-MCO-16-4-02510" position="float">
<label>Figure 1</label>
<caption><p>Plain radiographs of the knee. (A) Anteroposterior view shows an extraskeletal mass in the soft tissue at the medial aspect of the proximal tibia and saucerization of the tibial metaphysis. (B) Lateral view reveals cortical destruction as a moth-eaten appearance of the anterior proximal tibia.</p></caption>
<graphic xlink:href="mco-16-04-02510-g00.tif" />
</fig>
<fig id="f2-MCO-16-4-02510" position="float">
<label>Figure 2</label>
<caption><p>Computed tomography of the proximal tibia. (A) Sagittal plane shows lytic lesions from the proximal epiphyseal line to the tibial metaphysis. (B) Axial plane shows the formation of an extraskeletal mass and erosion of the anterior tibia.</p></caption>
<graphic xlink:href="mco-16-04-02510-g01.tif" />
</fig>
<fig id="f3-MCO-16-4-02510" position="float">
<label>Figure 3</label>
<caption><p>T1- and T2-weighted MRI. (A) On T1-weighted imaging, the bone tumor extending into extraosseous soft tissue appears homogeneously hypointense compared with bone. (B) On T2-weighted imaging, the bone tumor extending into extraosseous soft tissue exhibits signal hypointensity.</p></caption>
<graphic xlink:href="mco-16-04-02510-g02.tif" />
</fig>
<fig id="f4-MCO-16-4-02510" position="float">
<label>Figure 4</label>
<caption><p>Histopathological findings of a specimen obtained by open biopsy. (A) Hematoxylin and eosin staining demonstrated proliferatin of small, round to ovoid-shaped mesenchymal cells without osteoid formation (scale bar, 100 mm). (B) CD99 immunohistochemistry reveals patchy, weakly positive staining in membranes of tumor cells (magnification, x200). (C) Cyclin B3 immunohistochemistry shows strong, diffuse nuclear positivity (magnification, x200).</p></caption>
<graphic xlink:href="mco-16-04-02510-g03.tif" />
</fig>
<fig id="f5-MCO-16-4-02510" position="float">
<label>Figure 5</label>
<caption><p>Sanger sequencing of reverse transcription polymerase chain reaction product. Sequencing confirmed identical fusion points of <italic>BCOR</italic> exon 15 with <italic>CCNB3</italic> exon 5. CCNB3, cyclin B3; BCOR, BCL6 corepressor.</p></caption>
<graphic xlink:href="mco-16-04-02510-g04.tif" />
</fig>
<fig id="f6-MCO-16-4-02510" position="float">
<label>Figure 6</label>
<caption><p>FDG-PET/CT before treatment initiation and after neoadjuvant chemotherapy. (A) Increased FDG accumulation was observed in the tibial bone tumor before initiation of treatment, with a maximum SUV of 8.6. (B) FDG accumulation in tibial bone tumor after neoadjuvant chemotherapy was reduced, with a maximum SUV of 2.5. FDG, <sup>18</sup>F-fluoro-2-deoxyglucose; PET, positron emission tomography; CT, computed tomography; SUV, standardized uptake value.</p></caption>
<graphic xlink:href="mco-16-04-02510-g05.tif" />
</fig>
<table-wrap id="tI-MCO-16-4-02510" position="float">
<label>Table I</label>
<caption><p>Clinical features of <italic>BCOR-CCNB3</italic> fusion sarcoma of bone.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Author</th>
<th align="center" valign="middle">Cases</th>
<th align="center" valign="middle">Mean age, years (range)</th>
<th align="center" valign="middle">Sex (n)</th>
<th align="center" valign="middle">Location (n)</th>
<th align="center" valign="middle">Treatment (n)</th>
<th align="center" valign="middle">Outcome (n)</th>
<th align="center" valign="middle">Medan F-U (range)</th>
<th align="center" valign="middle">5-year OS rate</th>
<th align="center" valign="middle">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle" rowspan="8">Cohen-Gogo <italic>et al</italic> &#x005B;These 21 bone tumor cases included all cases in the article reported by Pierron <italic>et al</italic> (4)&#x005D;</td>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">13.6 (6-22)</td>
<td align="left" valign="middle">Male (14)</td>
<td align="left" valign="middle">Pelvis (8)</td>
<td align="left" valign="middle">EW (13)</td>
<td align="left" valign="middle">CR/Al (12)</td>
<td align="left" valign="middle">86 months (alive in sustained CR)</td>
<td align="center" valign="middle">76.5&#x0025;</td>
<td align="center" valign="middle">(<xref rid="b12-MCO-16-4-02510" ref-type="bibr">12</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Female (5)</td>
<td align="left" valign="middle">Femur (6)</td>
<td align="left" valign="middle">IA<sup>&#x002A;</sup> (5)</td>
<td align="left" valign="middle">DOD or De (9)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">NA (2)</td>
<td align="left" valign="middle">Spine (2)</td>
<td align="left" valign="middle">I<sup>&#x002A;</sup> (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Tibia (1)</td>
<td align="left" valign="middle">AML (1)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Toe (1)</td>
<td align="left" valign="middle">Local treatment</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Clavicle (1)</td>
<td align="left" valign="middle">only (1)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Talus (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Rib (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Puls <italic>et al</italic></td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">13.7 (11-16)</td>
<td align="left" valign="middle">Male 6</td>
<td align="left" valign="middle">Fibula 2</td>
<td align="left" valign="middle">VIDE-VAI (5)</td>
<td align="left" valign="middle">NED (5)</td>
<td align="left" valign="middle">78 months</td>
<td align="center" valign="middle">75&#x0025; (including <italic>BCOR-CCNB3</italic> sarcoma arising in soft tissue)</td>
<td align="center" valign="middle">(<xref rid="b13-MCO-16-4-02510" ref-type="bibr">13</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Female 1</td>
<td align="left" valign="middle">Pelvis (1)</td>
<td align="left" valign="middle">EVIAD (1)</td>
<td align="left" valign="middle">DOD (2)</td>
<td align="left" valign="middle">(5-189)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Pubic ramus (1)</td>
<td align="left" valign="middle">I, D, MTX (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Femur (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Tibia (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Calcaneus (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Peters <italic>et al</italic></td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">7</td>
<td align="left" valign="middle">Male</td>
<td align="left" valign="middle">Calcaneus</td>
<td align="left" valign="middle">VDC-IE</td>
<td align="left" valign="middle">DOD</td>
<td align="left" valign="middle">157 months</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(14)</td>
</tr>
<tr>
<td align="left" valign="middle">Shibayama <italic>et al</italic></td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">14.3 (11-17)</td>
<td align="left" valign="middle">Male (3)</td>
<td align="left" valign="middle">Pubis (2)</td>
<td align="left" valign="middle">VDC-IE (2)</td>
<td align="left" valign="middle">NED (3)</td>
<td align="left" valign="middle">80 months</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(<xref rid="b15-MCO-16-4-02510" ref-type="bibr">15</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Calcaneus (1)</td>
<td align="left" valign="middle">Osa (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">(7-102)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Ludwig <italic>et al</italic></td>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">13.1 (5-18)</td>
<td align="left" valign="middle">Male (6)</td>
<td align="left" valign="middle">Sacro-iliac joint (2)</td>
<td align="left" valign="middle">NA (6)</td>
<td align="left" valign="middle">NA</td>
<td align="left" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(<xref rid="b16-MCO-16-4-02510" ref-type="bibr">16</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Ilium (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Tibia (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Acetabulum (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Fibula (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Yamada <italic>et al</italic></td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">12</td>
<td align="left" valign="middle">Female</td>
<td align="left" valign="middle">Sacrum</td>
<td align="left" valign="middle">NA</td>
<td align="left" valign="middle">NA</td>
<td align="left" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(<xref rid="b17-MCO-16-4-02510" ref-type="bibr">17</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Matsuyama <italic>et al</italic></td>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Male (4)</td>
<td align="left" valign="middle">Sacrum (2)</td>
<td align="left" valign="middle">NA 4</td>
<td align="left" valign="middle">NED (4)</td>
<td align="left" valign="middle">75.5 months</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(<xref rid="b18-MCO-16-4-02510" ref-type="bibr">18</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Thoracic vertebra (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">(24-165)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Calcaneus (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Krskova <italic>et al</italic></td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">15</td>
<td align="left" valign="middle">Male</td>
<td align="left" valign="middle">Fibula</td>
<td align="left" valign="middle">NA</td>
<td align="left" valign="middle">DOD</td>
<td align="left" valign="middle">73 months</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(<xref rid="b19-MCO-16-4-02510" ref-type="bibr">19</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Kao <italic>et al</italic></td>
<td align="center" valign="middle">20</td>
<td align="center" valign="middle">14.3 (5-24)</td>
<td align="left" valign="middle">Male (19)</td>
<td align="left" valign="middle">Femur (5)</td>
<td align="left" valign="middle">VDC-IE (3)</td>
<td align="left" valign="middle">NED (7)</td>
<td align="left" valign="middle">45 months</td>
<td align="center" valign="middle">72&#x0025; (including <italic>BCOR-CCNB3</italic> sarcoma arising in soft tissue)</td>
<td align="center" valign="middle">(<xref rid="b20-MCO-16-4-02510" ref-type="bibr">20</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Female (1)</td>
<td align="left" valign="middle">Tibia (4)</td>
<td align="left" valign="middle">VD-IE (1)</td>
<td align="left" valign="middle">AWD (4)</td>
<td align="left" valign="middle">(10-113)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Calcaneus (3)</td>
<td align="left" valign="middle">EW (3)</td>
<td align="left" valign="middle">DOD (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Sacrum (3)</td>
<td align="left" valign="middle">Osa then EW (1)</td>
<td align="left" valign="middle">NA (8)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Ilium (2)</td>
<td align="left" valign="middle">Others (4)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Pubic ramus (2)</td>
<td align="left" valign="middle">NA (8)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Elbow (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Rekhi <italic>et al</italic></td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">6</td>
<td align="left" valign="middle">Male</td>
<td align="left" valign="middle">Tibia</td>
<td align="left" valign="middle">Regimen unclear</td>
<td align="left" valign="middle">AWD</td>
<td align="left" valign="middle">4 months</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(<xref rid="b21-MCO-16-4-02510" ref-type="bibr">21</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">25</td>
<td align="left" valign="middle">Male</td>
<td align="left" valign="middle">Vertebra</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">DOD</td>
<td align="left" valign="middle">8 months</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Brady <italic>et al</italic></td>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">14 (2-17)</td>
<td align="left" valign="middle">Male (4)</td>
<td align="left" valign="middle">Spine (2)</td>
<td align="left" valign="middle">VDC-IE (4)</td>
<td align="left" valign="middle">NED (4)</td>
<td align="left" valign="middle">22.4 months</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">(<xref rid="b22-MCO-16-4-02510" ref-type="bibr">22</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Female (1)</td>
<td align="left" valign="middle">Femur (1)</td>
<td align="left" valign="middle">Other (1)</td>
<td align="left" valign="middle">DOD (1)</td>
<td align="left" valign="middle">(2-41)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Tibia (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Pelvis (1)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Present case</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">12</td>
<td align="left" valign="middle">Male</td>
<td align="left" valign="middle">Tibia</td>
<td align="left" valign="middle">VDC-IE</td>
<td align="left" valign="middle">NED</td>
<td align="left" valign="middle">18 months</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>Ref., reference number; F-U, follow-up; NA, not available; EW, chemotherapy for Ewing sarcoma, but details unknown; IA<sup>&#x002A;</sup>, ifosfamide-adriamycin based chemotherapy; I<sup>&#x002A;</sup>, ifosfamide-based chemotherapy; AML, chemotherapy according to current acute myeloid leukemia protocol; V, vincristine; D, doxorubicin; C, cyclophosphamide; I, ifosfamide; E, etoposide; A, actinomycin D; MTX, methotrexate; Osa, chemotherapy according to osteosarcoma protocol; CR, complete remission; Al, alive; DOD, dead of disease; De, dead; NED, no evidence of disease; AWD, alive with disease; OS, overall survival.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
